Building an Effective [We Hope] Corporate Compliance Program Pragmatic Advice August 25, 2005 Roger W. Louis Chief Compliance Officer.

Slides:



Advertisements
Similar presentations
PRESENTATION ON MONDAY 7 TH AUGUST, 2006 BY SUDHIR VARMA FCA; CIA(USA) FOR THE INSTITUTE OF INTERNAL AUDITORS – INDIA, DELHI CHAPTER.
Advertisements

Chapter 6 Federal Regulation of Pharmacy Practice.
Corporate Compliance Instructor Notes:
COMPLIANCE AND INTEGRITY IN GOVERNMENT AND NON-PROFIT ORGANIZATIONS Michael E. Nawrocki, CPA Managing Partner Nawrocki Smith LLP, CPA’s Historical Perspective.
BNSF Ethics and Compliance Program Roger Nober Executive Vice President Law and Secretary July 13, 2011.
2010 Region II Conference Corporate Compliance Panel June 3, 2010
Chapter 29 Ethics in Accounting
WELCOME Annual Meeting & Compliance Seminar. Code of Conduct - Impact on Corporate Culture by Andy Greenstein Knight Capital Group, Inc.
Silo Compliance Risk vs. Enterprise Compliance Risk Presented to: ORIMS PD Day By: Joe Hardy & Tony Carlisle.
© 2013 Cengage Learning. All Rights Reserved. 1 Part Four: Implementing Business Ethics in a Global Economy Chapter 8: Developing an Effective Ethics Program.
Implementing and Auditing Ethics Programs
CORPORATE COMPLIANCE OVERVIEW David Meisels OSB Corporate Counsel Roundtable April 26, 2012.
Economics, Ethics and Markets
Corporate Ethics Compliance *
Control environment and control activities. Day II Session III and IV.
Internal Auditing and Outsourcing
© 2010 Dorsey & Whitney LLP Social Media Friday, September 17, 2010 The Committee on Finance & Information Technology (CFIT)
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
©PCaW London 20 July 2010.
© 2009 The McGraw-Hill Companies, Inc. All rights reserved. 1 McGraw-Hill Chapter 5 HIPAA Enforcement HIPAA for Allied Health Careers.
The Institutionalization of Business Ethics
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
HROFFICE USER CONFERENCE 2005 Creating an Effective Ethics and Compliance Program Ascentis User Group September, 2005.
CORPORATE COMPLIANCE Tim Timmons Vice President Compliance and Regulatory Services Health Future, LLC.
Institutional Research Compliance Juliann Tenney, JD Research Compliance and Privacy Officer Director, Institutional Research Compliance Program.
Home. Copyright © by The McGraw-Hill Companies, Inc. All rights reserved.Glencoe Accounting The accounting profession requires its members to follow a.
Developing and Implementing an Effective Compliance Program Mary Sacilotto,BA,CHC Chief Compliance Officer Alliance, Inc.
Developing an Effective Ethics Program
Purchasing Ethics and Vendor Relations
Managing the Privacy Function at a Large Company Kimberly S. Gray, Esq., CIPP Chief Privacy Officer Highmark Inc.
CORPORATE COMPLIANCE PROGRAM The Office of Corporate Integrity
Legal, Regulatory, and Political Issues
Corporate Responsibility and Compliance After Enron and Sarbanes-Oxley 6th National Congress on Health Care Compliance February 2003 John Bentivoglio
Sales and Marketing in the Pharmaceutical Industry: At the Vortex of the Perfect Legal Storm Paul E. Kalb, M.D., J.D. Princeton, N.J. - June 7, 2004.
Managerial Accounting and the Business Environment Class One.
Healthcare Compliance: 2014 Stuart Freedman, MPH HSC Chief Compliance Officer Monica Wilson, JD, CHC Manager, HSC Compliance.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
CODE OF CONDUCT TRAINING. We conduct our global business honestly, ethically and legally, believing that good ethics is good business. The Company’s Philosophy.
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
IT Professionalism Ethics Modified by Andrew Poon.
Current Issues in Pharmaceutical and Medical Device Compliance Management Introductory Comments Pharma, Medical Device & Biotech Colloquium June 6, 2005.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
Connecting the Dots A Practical Approach to Integrating Compliance, Risk and Quality Jody Ann Noon RN, JD Partner Health Care Regulatory Practice.
When Pharmaceutical Marketing Crosses the Line: Best Practices For Investigation and Remediation.
Implementing an Effective Global Anti-Bribery Program Implementing an Effective Global Anti-Bribery Program Elaine Murphy, MBA Director Health Care Compliance.
McGraw-Hill/Irwin Strategic Management, 10/e Copyright © 2007 The McGraw-Hill Companies, Inc. All rights reserved. Corporate Social Responsibility and.
Agenda for Session Compliance in Clinical Research
Welcome….!!! CORPORATE COMPLIANCE PROGRAM Presented by The Office of Corporate Integrity 1.
Standards of Conduct  Training today will give you talking points  You need to read through the book and get comfortable with the information  This.
Patrick Sulzberger, CPA, CHC Compliance & The Board A Guide to Excellence.
© Hogan & Hartson LLP. All rights reserved. US Compliance Risks and Strategies: An Overview Stephen J. Immelt June 6, 2007 International Pharmaceutical.
1 Pharmacy Management and Cost-Containment: Pharmaceutical Fraud Investigations, Prosecutions and Compliance Strategies John T. Bentivoglio
Lilly Answers that Matter. Preserving the Value of Industry Interactions with Health Care Professionals Jack Harris, M.D. Vice President, U.S. Medical.
California’s New Compliance Law Kelly N. Reeves
1 Compliance vs. the Law Department: How to Work Together Michael Dusseau Senior Director, Compliance North America Schering-Plough David Ralston, Esq.
Copyright © 2015 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
Compliance at the Crossroads: How can the Compliance Profession Move to the Second Generation? A Practical Approach to Integrating Compliance, Risk and.
Chapter 4 The Legal and Regulatory Environment of Health Care.
The accounting profession requires its members to follow a code of ethics.
MGMT 452 Corporate Social Responsibility
PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.
Welcome Back Glencoe Accounting.
Chapter 8 Developing an Effective Ethics Program
Risk Management: why and how to protect your health center
Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.
California’s “Comprehensive Compliance Program” Law
Compliance, Ethics, and Audit
Fy18-19 Compliance Plan Review & Board Member Training
ETHICAL CHALLENGES AND MANAGING RISK IN SOCIAL WORK PRACTICE
Presentation transcript:

Building an Effective [We Hope] Corporate Compliance Program Pragmatic Advice August 25, 2005 Roger W. Louis Chief Compliance Officer

2 Compliance: Some Etymology Regulatory –FDA/GMP/GCP Financial –SOX/SEC Legal –CMS/DOJ/OIG Commonalities & Differences –Sharing Best Practices –Establishing Systems & Processes Across Disciplines –Evolving Toward a Unified Field It’s All About Risk

3 Genzyme Corporate Compliance Program Established 1999 Initial Focus –$ in (Product Pricing & Price Reporting) –$ out (Financial Interaction with Health Care Professionals) Evolution –Antitrust –Privacy –Ad/prom –International –Sarbanes-Oxley –Ethics (Beyond the “Have to/Can’t do”) –Next???

4 What’s a Compliance Program & Why Have One? OIG Model Compliance Programs –Pharmaceuticals April Risk Management Device –OIG Risk Focus Drug Sampling Price Reporting Anti-kickback Evolution –False Claims Act PhRMA Guidelines –compliance will “substantially reduce risk of fraud and abuse”

5 The False Claims Act (“FCA”) Civil War Statute –Civil & Criminal Qui Tams (Whistleblowers) $11K per Claim & 3X$ Paid Huge Recoveries Creative Interpretations –That’s a claim! –Neurontin & FDA Ad/Prom Criminalizing off-label $430,000,000

6 FCA (cont.) What’s Next? Clinical Trials/GCP –Jim Sheehan comments FDA Risk Management Guidance –A floor, not a shield “Fraud on FDA & Fraud on the Public” GMP

7 Welcome to the Fun House State Level Activities –State Attorneys General; Spitzer et al –Legislation; e.g., California & the Phrma Code International –Proliferation of Enforcement Activities –FCPA Product Liability Exposure PR –Overdosed America: Broken promise of American Medicine-John Abramson –Bad Medicine-Jerome Kassirer –Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs-Jerry Avorn –The Truth About Drug Companies- Marcia Angell SOX

8 Corporate Compliance Programs The OIG Elements & Other Pragmatisms Policy Development Training Investigations/Audits/Reviews & “Check-Ups” Hot/Help lines Compliance Committee Code of Conduct Find the Right Outside Counsel “Hire a Good CEO”

9 Compliance Committee “Seek help immediately!!!” Complexity & Consensus Patience & Persuasion Managing the Matrix

10 Compliance Committee OIG Guidance: “The company should expect its compliance committee members and compliance officer to demonstrate high integrity, good judgment, assertiveness, and an approachable demeanor, while eliciting the respect and trust of company employees. These interpersonal skills are as important as the professional experience of the compliance officer and each member of the compliance committee.”

11 Compliance Committee “Manage the white space on the Org Chart” Influence Without (Formal) Authority Substance With Style –“Selling the Program” Forests & Trees –And branches & twigs

12 Code of Conduct Building Buy-in –From bottom up… to top down –From business unit… to corporate wide

13 Developing a Code of Conduct Identify: –Subject matter –Constituents –Scope –Industry best practices –Ownership –Implementation strategies

14 Elements of a Code of Conduct Internal Business Relationships –Confidential Information Inside Information Document Retention –Employees Complaint Resolution Process –Regulatory Compliance –Health, Safety and Environmental External Business Relationships –Trust and Integrity –Competitive Practices Product Information and Pricing Antitrust Health Care Laws –Conflicts of Interest Financial Interests and Business Relationships Gifts, Entertainment and Favors –Continuing Disclosure and Accurate Business Records –International Business –Lawful and Ethical Behavior

15 Developing a Code of Conduct: Other Considerations Compliance with the Code as an element of performance review Failures to comply, subject to disciplinary actions Documentation of receipt of Code Implementation and follow-up – distribution

16 Conclusions Systems & Processes vs. Substance Coordination Integration Unified Risk Management –Which risks –Who watches –Everyone is No One –But Only One is Not Enough